New Drugs for Follicular Lymphoma in Older Adults | Bentham Science
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

New Drugs for Follicular Lymphoma in Older Adults

Author(s): Anna Schmitt and Pierre Soubeyran

Volume 14, Issue 5, 2014

Page: [657 - 664] Pages: 8

DOI: 10.2174/1871523013666140416100814

Price: $65

Open Access Journals Promotions 2
Abstract

Follicular lymphoma is essentially a disease of the elderly, and the aging of the population in developed countries will increase patient numbers in coming years. Significant achievements have been made for treatment, but better understanding of the disease and major progress in biology now facilitate the development of many new drugs, which may have improved toxicity profiles making them appropriate for treatment of older adults. However, the increasing number of treatment possibilities, can also increase the toxicity risks, and unexpected toxicities specific to older adults may be encountered. Consequently, specific studies of older patients should be considered, using appropriate evaluation tools such as comprehensive geriatric assessment. This review will described the development of these new drugs, in the context of the treatment of older-adults with follicular lymphoma.

Keywords: Aged, elderly, Follicular lymphoma, frailty, new drugs, old, targeted therapies.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy